[4] Liebermann TR. Bacteremia and fiberoptic endoscopy. Gastrointest Endosc. 1976; 23(1):36–37
[5] Norfleet RG, Mitchell PD, Mulholland DD, Philo J. Does bacteremia follow upper gastrointestinal endoscopy? Am J Gastroenterol. 1981; 76(5):420–422
[6] O’Connor HJ, Hamilton I, Lincoln C. et al. Bacteraemia with upper gastrointestinal endoscopy--a reappraisal. Endoscopy. 1983; 15(1):21–23
[7] Chun YJ, Yoon NR, Park JM, et al. Prospective assessment of risk of bacteremia following colorectal stent placement. Dig Dis Sci. 2012; 57(4):1045–1049
[8] Barawi M, Gottlieb K, Cunha B, et al. A prospective evaluation of the incidence of bacteremia associated with EUS-guided fine-needle aspiration. Gastrointest Endosc. 2001; 53(2):189–192
[9] Levy MJ, Norton ID, Wiersema MJ, et al. Prospective risk assessment of bacteremia and other infectious complications in patients undergoing EUS-guided FNA. Gastrointest Endosc. 2003; 57(6):672–678
[10] Janssen J, König K, Knop-Hammad V, et al. Frequency of bacteremia after linear EUS of the upper GI tract with and without FNA. Gastrointest Endosc. 2004; 59(3):339–344
[11] Early DS, Acosta RD, Chandrasekhara V, et al; ASGE Standards of Practice Committee. Adverse events associated with EUS and EUS with FNA. Gastrointest Endosc. 2013; 77(6):839–843
[12] Levy MJ, Norton ID, Clain JE, et al. Prospective study of bacteremia and complications With EUS FNA of rectal and perirectal lesions. Clin Gastroenterol Hepatol. 2007; 5(6):684–689
[13] Zuccaro G, Jr, Richter JE, Rice TW, et al. Viridans streptococcal bacteremia after esophageal stricture dilation. Gastrointest Endosc. 1998; 48(6):568–573
[14] Nelson DB, Sanderson SJ, Azar MM. Bacteremia with esophageal dilation. Gastrointest Endosc. 1998; 48(6):563–567
[15] Hirota WK, Wortmann GW, Maydonovitch CL, et al. The effect of oral decontamination with clindamycin palmitate on the incidence of bacteremia after esophageal dilation: a prospective trial. Gastrointest Endosc. 1999; 50(4):475–479
[16] Camara DS, Gruber M, Barde CJ. et al. Transient bacteremia following endoscopic injection sclerotherapy of esophageal varices. Arch Intern Med. 1983; 143(7):1350–1352
[17] Cohen LB, Korsten MA, Scherl EJ. et al. Bacteremia after endoscopic injection sclerosis. Gastrointest Endosc. 1983; 29(3):198–200
[18] Brayko CM, Kozarek RA, Sanowski RA, Testa AW. Bacteremia during esophageal variceal sclerotherapy: its cause and prevention. Gastrointest Endosc. 1985; 31(1):10–12
[19] Snady H, Korsten MA, Waye JD. The relationship of bacteremia to the length of injection needle in endoscopic variceal sclerotherapy. Gastrointest Endosc. 1985; 31(4):243–246
[20] Lin OS, Wu SS, Chen YY, Soon MS. Bacterial peritonitis after elective endoscopic variceal ligation: a prospective study. Am J Gastroenterol. 2000; 95(1):214–217
[21] Berner JS, Gaing AA, Sharma R. et al. Sequelae after esophageal variceal ligation and sclerotherapy: a prospective randomized study. Am J Gastroenterol. 1994; 89(6):852–858
[22] da Silveira Rohr MR, Siqueira ES, Brant CQ, et al. Prospective study of bacteremia rate after elastic band ligation and sclerotherapy of esophageal varices in patients with hepatosplenic schistosomiasis. Gastrointest Endosc. 1997; 46(4):321–323
[23] Nelson DB. Infectious disease complications of GI endoscopy: Part I, endogenous infections. Gastrointest Endosc. 2003; 57(4):546–556
[24] Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee. American Heart Association Council on Cardiovascular Disease in the Young. American Heart Association Council on Clinical Cardiology. American Heart Association Council on Cardiovascular Surgery and Anesthesia. Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007; 116(15):1736–1754
[25] Khashab MA, Chithadi KV, Acosta RD, et al; ASGE Standards of Practice Committee. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2015; 81(1):81–89
[26] Khashab MA, Tariq A, Tariq U, et al. Delayed and unsuccessful endoscopic retrograde cholangiopancreatography are associated with worse outcomes in patients with acute cholangitis. Clin Gastroenterol Hepatol. 2012; 10(10):1157–1161
[27] Kapral C, Mühlberger A, Wewalka F, et al. Working Groups Quality Assurance and Endoscopy of Austrian Society of Gastroenterology and Hepatology (OeGGH). Quality assessment of endoscopic retrograde cholangiopancreatography: results of a running nationwide Austrian benchmarking project after 5 years of implementation. Eur J Gastroenterol Hepatol. 2012; 24(12):1447–1454
[28] Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007; 102(8):1781–1788
[29] Barkay O, Khashab M, Al-Haddad M, Fogel EL. Minimizing complications in pancreaticobiliary endoscopy. Curr Gastroenterol Rep. 2009; 11(2):134–141
[30] Colton JB, Curran CC. Quality indicators, including complications, of ERCP in a community setting: a prospective study. Gastrointest Endosc. 2009; 70(3):457–467
[31] Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001; 96(2):417–423
[32] Ismail S, Kylänpää L, Mustonen H, et al. Risk factors for complications of ERCP in primary sclerosing cholangitis. Endoscopy. 2012; 44(12):1133–1138
[33] Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998; 48(1):1–10
[34] Bilbao MK, Dotter CT, Lee TG, Katon RM. Complications of endoscopic retrograde cholangiopancreatography (ERCP). A study of 10,000 cases. Gastroenterology. 1976; 70(3):314–320
[35] Sauter G, Grabein B, Huber G. et al. Antibiotic prophylaxis of infectious complications with endoscopic retrograde cholangiopancreatography. A randomized controlled study. Endoscopy. 1990; 22(4):164–167
[36] Niederau C, Pohlmann U, Lübke H, Thomas L. Prophylactic antibiotic treatment in therapeutic or complicated diagnostic ERCP: results of a randomized controlled clinical study. Gastrointest Endosc. 1994; 40(5):533–537
[37] Brand M, Bizos D, O’Farrell P, Jr. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography. Cochrane Database Syst Rev. 2010(10):CD007345
[38] Motte S, Deviere J, Dumonceau JM. et al. Risk factors for septicemia following endoscopic biliary stenting. Gastroenterology. 1991; 101(5):1374–1381
[39] De Palma GD, Galloro G, Siciliano S. et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc. 2001; 53(6):547–553
[40] Bangarulingam SY, Gossard AA, Petersen BT. et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol. 2009; 104(4):855–860
[41] Byl B, Devière J, Struelens MJ, et al. Antibiotic prophylaxis for infectious complications after therapeutic endoscopic retrograde cholangiopancreatography: a randomized, double-blind, placebo-controlled study. Clin Infect Dis. 1995; 20(5):1236–1240
[42] Saxena P, Singh VK, Lennon AM. et al. Endoscopic management of acute cholecystitis after metal stent placement in patients with malignant biliary obstruction: